Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of LM-302 in CLDN18.2-positive advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
CTR20240955Phase 3Active
- Sponsor
- LaNova Medicines
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tpx-4589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by LaNova Medicines. Started Jun 2024; status: active.
02
Drugs
tpx-4589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20240955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240955.